Merck Gets FDA Nod for Intravenous Noxafil

The FDA has approved Merck’s Noxafil 18 mg/mL antifungal injection for use against invasive Aspergillus and Candida infections in high-risk patients ages 18 and older, the drug giant said.

Friday’s approval for an intravenous version of Noxafil (posaconazole) adds to Merck’s already available 100 mg delayed-release tablets and 40 mg/mL oral suspension, both of which are indicated for patients ages 13 and older.

Merck plans to make the intravenous drug commercially available in the U.S. in mid-April. — Lena Freund

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.